USA flag logo/image

An Official Website of the United States Government

Anti-angiogenesis of HC-HA Covalent Complex and PTX3 Purified from Fetal…

Award Information

Agency:
Department of Health and Human Services
Branch:
N/A
Award ID:
Program Year/Program:
2011 / SBIR
Agency Tracking Number:
R43EY021045
Solicitation Year:
2011
Solicitation Topic Code:
NEI
Solicitation Number:
PA10-050
Small Business Information
TISSUETECH, INC.
7000 SW 97 AVENUE SUITE 212 MIAMI, FL -
View profile »
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No
 
Phase 1
Fiscal Year: 2011
Title: Anti-angiogenesis of HC-HA Covalent Complex and PTX3 Purified from Fetal Membrane
Agency: HHS
Contract: 1R43EY021045-01A1
Award Amount: $239,951.00
 

Abstract:

DESCRIPTION (provided by applicant): Angiogenesis is a part of adult wound healing, which starts from inflammation and may end in scarring. When inflammation, angiogenesis, and scarring are well controlled, adult wound healing results in the restoration oftissue function. In contrast, pathologic angiogenesis that is frequently associated with uncontrolled inflammation may lead to pathologic scarring. In the eye, where vision is the key function, any such scar-prone wound healing can lead to blindness. In fact, the NIH has recognized that the inability of chronic wounds to heal is a major health problem in the United States and that such a problem will increase in magnitude as the population ages. We have long speculated that one novel solution to the aforementioned problem lies in a better understanding of the biological function of the fetal membrane, which consists of the amniotic membrane (AM) and the chorion (CH). Our speculation is derived partly from cumulative clinical successes of AM transplantationin delivering anti-inflammatory, anti- scarring, and anti-angiogenic efficacies to the ocular surface, as well as from the mystery of fetal wound healing that lacks inflammation and angiogenesis, and is scarless . We have successfully purified the covalent HC HA complex formed between hyaluronan (HA) and the heavy chain (HC) of inter- -inhibitor (I I) from the AM and has identified it as one active component that exerts anti-inflammatory, anti-scarring and anti-angiogenic actions. We have further gatheredstrong evidence supporting that HC HA purified from the CH is 25 fold more potent than that purified from the AM and that PTX3 from the CH may enhance the HC HA's suppression of vascular endothelial proliferation. In this Phase I application, we thus propose to delineate the chemical structure of HC HA by verifying that PTX3 is indeed the key protein from CH to enhance HC HA's anti-angiogenic action (Aim 1); and to characterize and compare the in vitro anti-angiogenic action of HC HA purified from the CH tothat from AM (Aim 2). Together with the study to be supported by a Phase II (R44 EY017497) grant, which focuses on testing in vivo anti-inflammatory and anti-scarring efficacies by HC HA purified from the AM, we believe that successful completion of the above two aims will let us put forth a novel therapeutic paradigm, for the first time, where a single HC HA complex can simultaneously curtail three key steps, i.e., inflammation, angiogenesis, and scarring of adult wound healing. As a result, we envision that HC HA may not only be an embryonic matrix responsible for ensuring scarless fetal wound healing, but it can also be sufficiently harnessed from the fetal membrane as a novel biomaterial, from which we may launch new therapeutics to gear adult wound healing towards regeneration. By including PTX3 to HC HA, we may develop a new class of angiogenesis inhibitors for treating many diseases in and beyond ophthalmology where pathologic angiogenesis threatens our vision and health. PUBLIC HEALTH RELEVANCE: The research described in this Phase I application is aimed at developing a novel class of angiogenesis inhibitors that are based on the covalent HC HA complex formed between hyaluronan (HA) and the heavy chain (HC) of inter- -inhibitor and purified from the fetal membrane, i.e., the amniotic membrane and the chorion. Our proposed research intends to prove that PTX3, a pentraxin family member known to exert both anti-angiogenic and anti- inflammatory actions, first, is strongly associated with HC HA purified from the chorion and, second, is responsible for enhancing the anti-angiogenic potency of HC HA. We believe that PTX3 can be added to HC HA to produce a new class of angiogenesis inhibitors, which will not only suppress angiogenesis mediated by bFGF and VEGF but will also be more useful and effective by curtailing additional inflammation and scarring. Consequently, we may develop new therapeutics based on PTX3 bound to HC HA to treat many diseases in and beyond ophthalmology where unwanted angiogenesisis detrimental to our vision and health.

Principal Investigator:

Scheffer C. Tseng
305-274-1299
stseng@ocularsurface.com

Business Contact:

Nelson A. Vega
305-412-0098
nvega@tissuetechinc.com
Small Business Information at Submission:

TISSUETECH, INC.
7000 SW 97 AVENUE SUITE 212 MIAMI, FL -

EIN/Tax ID: 165111607
DUNS: N/A
Number of Employees: N/A
Woman-Owned: Yes
Minority-Owned: No
HUBZone-Owned: No